Comparative Pharmacology
Head-to-head clinical analysis: DEMI REGROTON versus NORMOZIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DEMI REGROTON versus NORMOZIDE.
DEMI-REGROTON vs NORMOZIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
DEMI-REGROTON is a fixed-dose combination of chlorothiazide (a thiazide diuretic) and reserpine (a Rauwolfia alkaloid). Chlorothiazide inhibits the Na+-Cl- symporter in the distal convoluted tubule, reducing sodium and water reabsorption. Reserpine depletes catecholamines (norepinephrine, dopamine, serotonin) from central and peripheral nerve endings by inhibiting vesicular monoamine transporter 2 (VMAT2), leading to reduced sympathetic outflow and vasodilation.
Normozide is a combination of prazosin and polythiazide. Prazosin blocks alpha-1 adrenergic receptors, causing vasodilation and reduced peripheral resistance. Polythiazide inhibits sodium reabsorption in the distal convoluted tubule, increasing excretion of sodium and water.
One tablet orally once daily, each tablet containing 25 mg chlorthalidone and 0.125 mg reserpine.
Oral: 10 mg once daily. Maximum dose: 20 mg once daily.
None Documented
None Documented
Terminal elimination half-life is 40-60 hours (mean 48 h), allowing once-daily dosing; steady state reached in 5-7 days
Terminal elimination half-life is 8-12 hours in patients with normal renal function; prolonged to 20-30 hours in renal impairment (CrCl <30 mL/min). Clinical context: Dosing interval adjustments are required in renal disease to avoid accumulation.
Renal: 70% as unchanged drug; biliary/fecal: 30% as metabolites
Renal excretion accounts for approximately 70% of elimination (30% as unchanged drug, 40% as inactive metabolites). Biliary/fecal elimination constitutes about 25%, with the remainder undergoing metabolic clearance.
Category C
Category C
Antihypertensive Combination
Antihypertensive Combination